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Background: Metabolic syndrome (MetS) present in type 2 diabetic patients greatly increases the risk of strokes and
cardiovascular diseases. Timely detection and mapping of MetS facilitates appropriate preventive and therapeutic
approaches to minimize these risks. Our study aimed to determine the prevalence of MetS among Nepalese type 2
diabetic patients using WHO (1999), NCEP ATP III (2001), IDF (2005) and Harmonized (2009) definitions and identify the
diagnostic concordance and disparity resulting from these four definitions.
Methods: Clinical and biochemical data were collected for 1061 type 2 diabetic patients at Manipal Teaching Hospital,
Pokhara, Nepal. The data was analyzed in order to identify prevalence of MetS in these patients. Statistical analysis
included usage of Student’s t- and Chi-square tests, kappa statistics and 95% confidence intervals.
Results: The total age adjusted prevalence rates of MetS were 80.3%, 73.9%, 69.9% and 66.8% according to Harmonized,
NCEP ATP III, WHO and IDF definitions, respectively. Prevalence increased with the age and was higher in females
(p <0.001) according to WHO, NCEP ATP III and Harmonized definitions. Patients of Dalit community had the
highest prevalence (p<0.05) according to NCEP ATP III and Harmonized definitions while Mongoloid and Newar
patients had the highest prevalence (p <0.05) according to WHO and IDF definitions, respectively. Prevalence was
also highest among patient engaged in agriculture occupation. Central obesity and hypertension were respectively the
most and the least prevalent components of MetS. The highest overall agreement was between Harmonized and
NCEP ATP III definitions (κ =0.62, substantial) and the lowest between WHO & IDF definitions (κ=0.26, slight). The
Harmonized definition had the highest sensitivity (99.9%) and negative predictive value (98.9%) while NCEP ATP III
definition had the highest specificity (98.9%) and positive predictive values (99.9%) in identifying the cases of MetS.
Conclusions: The prevalence of MetS among Nepalese type 2 diabetic patients was very high suggesting that these
patients were at increased risk of strokes, cardiovascular diseases and premature death. The Harmonized definition was
the most sensitive while NCEP ATP III and IDF definitions were the most specific in detecting the presence of MetS in
Nepalese type 2 diabetic patients.
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Metabolic syndrome (MetS) is a cluster of intercon-
nected metabolic disorders that includes insulin resist-
ance, dysglycemia, central obesity, high triglycerides, low
high density lipoprotein cholesterol and hypertension [1].
Recent inclusion of additional metabolic disorders such as
chronic pro-inflammatory and prothrombotic states, non-
alcoholic fatty liver disease and sleep apnea has made this
definition even more complex. Existence of three or more
of these disorders warrants the diagnosis of this syndrome.
Metabolic syndrome has been shown to increase the risk
of cardiovascular diseases (CVDs) by two fold and type 2
diabetes mellitus (DM) approximately by five folds over 5
to 10 years [2-4].
There is still lack of clearly defined pathophysiology and
universal definition of MetS. Many researchers question its
own existence as a specific syndrome and believe that it is
instead a surrogate of combined syndrome that predisposes
an individual to particular risk. This has led to several defi-
nitions for MetS being proposed by various international
regulatory bodies [1]. World Health Organization (WHO)
defines this syndrome as the presence of glucose intoler-
ance or insulin resistance or diabetes mellitus with any two
of the following components: obesity, high serum triglycer-
ides, low serum high density lipoprotein cholesterol and
hypertension [5]. The National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III)
describes metabolic syndrome as the presence of any
three of the following components: abdominal obesity,
dyslipidemia (high levels of triglycerides, low HDL),
hypertension, and elevated fasting glucose [6]. The
International Diabetes Federation (IDF) takes central
obesity as a mandatory component for the diagnosis of
MetS along with any two of the other components: hyper-
tension, abnormal blood glucose, high serum triglycerides
and low high density lipoprotein cholesterol [7]. Recently,
IDF, National Heart, Lung and Blood Institute (NHLBI),
American Heart Association (AHA), World Heart Feder-
ation (WHF), International Atherosclerosis Society (IAS)
and International Association for the Study of Obesity
(IASO) have proposed a new harmonized definition
which requires any three of the five components in-
cluded in the IDF definition for the diagnosis of MetS
and do not consider central obesity as an obligatory
component [8].
Prevalence of type 2 diabetes mellitus is increasing
very rapidly, particularly in developing countries of the
world resulting in a substantial burden on the healthcare
services [9]. Approximately 9.5% of the Nepalese popula-
tion suffers from the type 2 diabetes mellitus [10]. Ma-
jority of the type 2 diabetic patients also have MetS and
are predisposed to higher risk of cardiovascular diseases,
strokes and premature death compared to both non-
diabetic individuals and diabetic individuals withoutMetS [11-13]. Presence of MetS in the type 2 diabetic
patients has been shown to decrease the survival rate at
least by 10 years [14]. Despite controversies on its own
existence and universally accepted definition, metabolic
syndrome is still a useful concept which helps identify
diabetic patients at high risk of developing atheroscler-
otic CVDs and stroke and predict all cause mortality
[1,14]. Moreover, it also helps clinical researchers better
understand the pathophysiology that culminates in the
CVDs and stroke and formulate preventive and thera-
peutic approaches. Except for a few preliminary studies
[15-18], there has been no systematic study in Nepal
that determines the prevalence of MetS in type 2
diabetic populations and diagnostic performance of the
available defining criteria. The aim of this study is there-
fore to estimate the prevalence of MetS in type 2 dia-
betic patients using four most popular diagnostic criteria
viz. WHO (1999), NCEP ATP III (2001), IDF (2005) and
Harmonized (2009) (Table 1) and determine their level
of agreement and disparity in the diagnosis of MetS. The
results of this study will provide template epidemiological
data for conducting nationwide prevalence surveys, for-
mulation of national strategies for the prevention and
control of MetS, type 2 diabetes and CVDs in Nepal.
Methods
Study design and patients
This was a cross-sectional study conducted from July
2012 to August, 2013 at Manipal Teaching Hospital
(MTH), Pokhara, Nepal. The study protocol was ap-
proved by the institutional ethical committee and in-
formed consent was obtained from all the enrolled study
patients for their inclusion in the screening and partici-
pation in the research. A total of 1061 type 2 diabetic
patients without any diabetes related complications and
other acute or chronic illness were selected from the
various out-patient departments of MTH and enrolled
for this study. Presence of type 2 diabetes mellitus was
ascertained clinically based on the criteria defined by
WHO for diabetes mellitus, age of onset of diabetes and
types of medications being prescribed [19]. Patients with
established cardiovascular diseases, thyroid dysfunction,
excessive alcohol or other drug abuse, current psychiatric
treatment and current or recent (up to 4 months) preg-
nancy were excluded to homogenize the study subjects.
The subjects were 30–89 years old and hailed mainly from
Gandaki, Dhaulagiri, Lumbini and other adjoining zones
of the Western Development Region of Nepal.
Anthropometric, physiological and lifestyle related
variables
All the study patients were personally interviewed by the
trained interviewers within the hospital premises using a
pre-validated set of questionnaire and details of their
Table 1 Criteria for clinical diagnosis of the metabolic syndrome (MetS) according to various definitions
Criteria WHO (1998) NCEP (2001) IDF (2005) Harmonized (2009)
Prerequisite DM, IFG, IGT, IR None WC: ≥90 cm (men) &
≥80 cm (women)†
None
No. of other criteria and ≥2 of: ≥3 of: and ≥2 of: ≥3 of:
Obesity BMI: ≥30 &/or WHR: >0.9
(men) & >0.85 (women)




WC: ≥90 cm (men) &
≥80 cm (women)†
BP (mmHg) ≥140/90 ≥130/85 or Rx ≥130/85 or Rx ≥130/85 or Rx
HDL-C (mg/dl) <35 (men) & <39 (women) or <40 (men) &
<50 (women) or Rx
<40 (men) &
<50 (women) or Rx
<40 (men) &
<50 (women) or Rx
TG (mg/dl) ≥150 ≥150 or Rx ≥150 or Rx ≥150 or Rx
Fasting glucose (mg/dl) ≥110, IGT ≥100 or Rx ≥100 or Rx ≥100 or Rx
Microalbuminuria Urinary albumin ≥20 μg/min or
albumin-creatinine ratio >30 mg/g
- - -
†Recommended waist circumference thresholds for the abdominal obesity in people of Asian origin.
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dietary habits, ethnicity and profession were recorded.
Height, weight, waist and hip circumferences of these
patients were measured following the standard protocols
and were used for calculating their BMI and WHR.
Recent WHO guideline for South Asian population
(18.5-22.9 kg/m2) was followed to classify their BMI sta-
tus [20]. Blood pressure was measured in triplicate while
on the sitting position using digital sphygmomanometer
(TaiDoc Technology Corporation, Taiwan).
Biochemical investigations in the blood samples
Five ml of fasting venous blood sample was drawn from
each subject and then divided into fluoride-oxalate vials,
EDTA vacutainers and plain test tubes. Plasma fasting
glucose was measured by glucose oxidase/peroxidase
method using blood collected in fluoride-oxalate vials.
Glycated hemoglobin (HbA1C) was measured on EDTA
blood by ion-exchange resin method. Serum triglycerides
(TG), total cholesterol (TC) and HDL-cholesterol (HDL-C)
were directly measured on plain blood and then LDL-
cholesterol value was calculated using Friedwald formula
[21]. All these parameters were analyzed at the Clinical
Biochemistry laboratory of MTH using semi-automated
chemistry analyzer (Humalyzer-3500) and ready-to-use
reagent kits according to the protocols provided by
the manufacturer (Human diagnostics, Germany). For
serum lipid reference level, NCEP ATP III guideline
was referred [6]. According to this, hypercholesterol-
emia was defined as TC >200 mg/dl, high LDL-C when
value >100 mg/dl, hypertriglyceridemia as TG >150 mg/dl
and low HDL-C when value <40 mg/dl. Dyslipidemia was
defined by the presence of one or more abnormal serum
lipid concentration.
Statistical analysis
Statistical analysis was performed by SPSS, version 17.0 for
Windows (SPSS, IL, Chicago, USA). Data for categoricalvariables are expressed either in number and percentage
(N,%) or percentage and 95% confidence intervals (95%
CI). 95% CIs for crude and age standardized rates were
calculated according to the modified Wald method and
Keyfitz formulas, respectively [22,23]. Standard error values
of age standardized rate were calculated by binomial ap-
proximation. Numerical data for continuous variables were
expressed in the form of mean ± standard deviation. The
age-standardized prevalence rates were calculated with
the direct method, using the standard population of
Nepal estimated by National Population and Housing
Census in 2011 [24]. The agreements among the defini-
tions of WHO, NCEP ATP III, IDF and harmonized
criteria were assessed with kappa statistics. The level of
agreement was categorized as poor with κ ≤0.20, fair
with κ =0.21 to 0.40, moderate with κ =0.41 to 0.60, sub-
stantial with κ =0.61 to 0.80, and very good with κ >0.80
[25]. Pearson’s Chi-square test (asymp.sig, 2 sided) and In-
dependent sample test (p values, 2 tailed) were used for
checking the statistical significance of difference between
the proportion and mean values of two or more groups of
variables respectively. The tests were considered statisti-
cally significant when p <0.05.
Results
Baseline characteristics of the study patients
The frequency analysis of socio-demographic, anthro-
pometric, clinical and biochemical parameters of study
patients are given in Table 2. A total of 1061 type 2 dia-
betic patients (male: 589 and female: 472) were enrolled
in the present study, with a male to female ratio of about
1.25:1. The mean age of the patients was 56.4 ±10 years
and the durations of type 2 diabetes and hypertension
were 6.0 ±4.6 and 3.8 ±5.5 years respectively with
no significant difference (p >0.05) between males and
females. Their ethnic backgrounds were Brahmin (261,
24.6%), Chhetri (253, 23.8%), Dalit (102, 9.6%), Mongol
(348, 32.8%) and Newar (97, 9.1%). Seven hundred forty
Table 2 Frequency analysis of socio-demographic and
anthropometric parameters of the study subjects
Characteristic variables Male Female p-value* Total
n (%) 589 (55.5) 472 (44.5) 1061 (100)
Ethnic groups
Brahmin 145 (24.6) 116 (24.6) <0.010 261 (24.6)
Chhetri 163 (27.7) 90 (19.1) 253 (23.8)
Dalit 57 (9.7) 45 (9.5) 102 (9.6)
Mongol 169 (28.7) 179 (37.9) 348 (32.8)
Newars 55 (9.3) 42 (8.9) 97 (9.1)
Occupation
Agriculture 164 (27.8) 345 (73.1) <0.001 509 (48.0)
Business 251 (42.6) 67 (14.2) 318 (30.0)
Office job 174 (29.5) 60 (12.7) 234 (22.1)
Place of residence
Urban 428 (72.7) 321 (68.0) <0.001 749 (70.6)
Village 161 (27.3) 151 (32.0) 312 (29.4)
Smoking habit
Non-smokers 338 (54.7) 334 (70.8) 672 (63.3)
Current smokers 108 (18.3) 76 (16.1) <0.001 184 (17.3)
Ex-smokers 143 (24.3) 62 (13.1) 205 (19.3)
Dietary habit
Vegetarian 62 (10.5) 63 (13.3) <0.001 125 (11.8)
Non-vegetarian 527 (89.5) 409 (86.7) 936 (88.2)
General obesity 127 (21.6) 161 (34.1) <0.001 288 (27.1)
Central obesity
Android 448 (76.1) 216 (45.8) <0.001 664 (62.6)
Gyenoid 111 (18.8) 236 (50.0) 347 (32.7)
Glycemic control
Good (≤6.5%) 589 (100.0) 461 (97.7) <0.001 1050 (99.0)
Suboptimal (≥6.5%) 0 (0) 11 (2.3) 11 (1.0)
Dyslipidemia
High TG 377 (64.0) 323 (68.4) <0.001 700 (66.0)
Low HDL-C 464 (78.8) 378 (80.1) 842 (79.4)
Hypertension (HTN) 410 (52.4) 357 (52.1) <0.001 555 (32.3)
Treatment for HTN 281 (47.7) 243 (51.5) <0.001 524 (49.4)
Values are presented as n (%). *p-values (2-tailed): Chi-square test was performed
to compare the proportions of selected demographic, anthropometric and
biochemical characteristics between male and female diabetic patients.
Table 3 Anthropometric, biochemical and clinical
parameters of the type 2 diabetic patients
Characteristic
variables
Male Female p-value* Total
n 589 472 - 1061
Age (years) 56.4 ±9.6 56.4 ±10.4 >0.050 56.4 ±10.0
BMI (m/kg2) 23.2 ±2.7 24.1 ±2.8 <0.001 23.6 ±2.8
WC (cm) 95.0 ±8.5 96.7 ±10.1 <0.010 95.8 ±9.3
WHR 1.1 ±0.1 1.0 ±0.1 <0.001 1.0 ±0.1
FPG (mg/dl) 132.2 ±37.6 129.8 ±28.3 >0.05 131.1 ±33.8
2 hr PMG (mg/dl) 217.2 ±70.7 219.1 ±50.3 >0.05 218.1 ±62.4
EAG (mg/dl) 131.1 ±19.3 135.8 ±22.7 <0.001 133.2 ±21.0
HbA1C (%) 6.2 ±0.7 6.4 ±0.8 <0.001 6.3 ±0.7
Duration of
DM (year)
5.8 ±4.7 6.3 ±4.6 >0.050 6.0 ±4.6
TG (mg/dl) 188.3 ±117.4 229.6 ±236.7 <0.010 206.7 ±181.6
TC (mg/dl) 227.4 ±59.1 231.3 ±74.5 >0.050 229.1 ±66.4
VLDL (mg/dl) 37.7 ±23.4 45.8 ±27.4 <0.010 41.3 ±36.3
HDL-C (mg/dl) 31.9 ±7.6 30.7 ±8.2 <0.050 31.4 ±7.9
LDL-C (mg/dl) 157.8 ±63.7 154.8 ±55.7 >0.050 156.5 ±60.2
SBP (mmHg) 132.4 ±13.8 132.6 ±17.4 >0.050 132.5 ±15.5
DBP (mmHg) 83.4 ±7.7 81.9 ±9.9 <0.010 82.8 ±8.8
Duration of
HTN (year)
3.6 ±4.9 4.2 ±6.2 >0.050 3.8 ±5.5
Values are presented as mean ± standard deviation. *p-values (2-tailed): Student’s
t-test was used to compare the mean values of selected biochemical and
anthropometric characteristics between male and female diabetic patients.
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(29.9%) were from villages. Their major occupations
were agriculture (509, 48.0%), business (318, 30.0%) and
office jobs (234, 22.1%). All subjects were under medi-
cation for diabetes mellitus, out of which 524 (49.4%)
were also undertaking treatment for hypertension. In
terms of BMI statuses, thirty (2.8%) individuals were
underweight, 306 (28.8%) were at high risk group, 255(24.0%) were obese type I and 33 (3.1%) were obese
type II. Waist circumference was increased in 305
(28.7%) and substantially increased in 483 (45.5%) sub-
jects. The waist-hip ratio was increased in 861 (81.1%)
subjects among which 664 (62.6%) had android and 347
(32.7%) had gyenoid type central obesity. There were
125 (11.8%) vegetarian, 936 (88.2%) non-vegetarian, 184
(17.3%), smoker, 205 (19.3%), ex-smoker and 672 (63.3%)
non-smoker patients. 1050 (99.0%) patients had good gly-
cemic control while only 11 (1.0%) patients had subopti-
mal glycemic control. Serum triglycerides were borderline
high in 303 (28.6%), high in 373 (35.2%) and very high in
24 (2.3%) subjects. Likewise, serum total cholesterol level
was borderline high in 323 (30.4%) and very high in 373
(35.2%) subjects. Serum HDL cholesterol was lower than
normal in 842 (79.4%) subjects. There were 263 (24.8%)
subjects in pre-hypertensive stage, 343 (32.3%) in hyper-
tensive stage I and 212 (20.0%) in hypertensive stage II
and 524 (49.4%) patients were taking medicine for hyper-
tension. The proportion of these parameters differed
significantly (p <0.010) between male and female subjects.
The mean values of various anthropometric, clinical
and biochemical parameters of the male and female
study patients are presented in Table 3. When compared
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mean values of BMI, waist circumference, estimated
average glucose, HbA1c, triglycerides, very low density
lipoprotein, high density lipoprotein cholesterol and
diastolic blood pressure (p <0.010). Only the waist to hip
ratio was significantly higher (p <0.001) in males com-
pared to females. The gender wise difference was not
statistically significant for other parameters (p >0.05).
Crude, sex and age-adjusted prevalence of metabolic
syndrome
Both age and sex-specific crude and age adjusted preva-
lence of MetS estimated by using WHO, NCEP ATP III,
IDF and Harmonized criteria are given in the Table 4.
Most patients met the criteria for metabolic syndrome,
and the proportion of patients without metabolic syn-
drome was relatively small. The total crude prevalence
was 81.1%, 83.0%, 80.5% and 91.6% according to WHO,
NCEP ATP III, IDF and Harmonized criteria, respect-
ively. The corresponding age-adjusted total prevalence
was 69.9%, 73.9%, 66.8% and 80.3% respectively. The
Harmonized definition outperformed other definitions
in diagnosing the cases of MetS. The prevalence was
significantly higher in females (p <0.001) than in males
except for the one diagnosed by IDF definition. PrevalenceTable 4 Age and sex-specific and age-adjusted prevalence of
Age group (years) Prevalence of MetS (WHO) (%)
Male Female *p-value
n 589 472 -
30-39 14 (50.0) 15 (50.0) >0.050
40-49 88 (67.2) 60 (67.4) >0.050
50-59 157 (84.4) 148 (95.5) <0.010
60-69 151 (83.9) 111 (82.2) >0.050
≥70 61 (95.3) 56 (88.9) >0.050
Sex-specific crude 471 (80.0) 390 (82.6) >0.050
Total crude 861 (81.1)
Total age-adjusted 69.9
Age group (years) Prevalence of MetS (IDF) (%)
Male Female *p-value
n 589 472 -
30-39 4 (14.3) 18 (60.0) <0.001
40-49 91 (69.5) 77 (86.5) <0.010
50-59 152 (81.7) 153 (98.7) <0.001
60-69 121 (67.2) 135 (100) <0.001
≥70 37 (63.8) 58 (98.3) <0.001
Sex-specific crude 410 (69.6) 444 (94.1) <0.001
Total crude 854 (80.5)
Total age-adjusted 66.8
Values are expressed as n (%) or only%. *p-values (2-tailed): Chi square test was use
female diabetic patients.generally increased with the increase in age and remained
highest in the age range of 50–69 years in both the sexes.
The peak prevalence age group, however, was different for
males (50–59 years) and females (70–79 years). Prevalence
was at the lower end in the age groups of 30–40 and
80–89 years for both the sexes. Total prevalence of
metabolic syndrome was higher among patients living
in the urban area according to WHO, NCEP ATPIII
and Harmonized definitions and in villages according
to IDF definition. However, the difference was signi-
ficant only with WHO estimated prevalence (p <0.002)
(Table 5). On the other hand, according to NCEP
ATPIII, IDF and Harmonized definitions, prevalence
was much higher (p <0.020) among the female patients
living in the villages compared to their urban counter-
parts. Females had also higher prevalence compared to
their male counterparts living in the same places except
for the WHO defined prevalence in the urban patients.
Likewise, Dalit patients had the highest total prevalence
(p <0.05) according to NCEP ATPIII and Harmonized
definitions while Mongol and Newar patients had
the highest (p <0.010) total prevalence according to
WHO and IDF definitions respectively. Sex-wise ana-
lysis revealed that Mongol and Dalit male patients had
the highest (p <0.010) prevalence according to WHO,metabolic syndrome in the type 2 diabetic patients
Prevalence of MetS (NCEP ATPIII) (%)
Male Female *p-value
589 472 -
14 (50.0) 16 (53.3) >0.050
103 (78.6) 82 (92.1) <0.010
145 (78.0) 147 (94.8) <0.001
143 (79.4) 122 (90.4) <0.010
57 (89.1) 55 (87.3) >0.050
462 (78.4) 422 (89.4) <0.001
884 (83.3)
73.9
Prevalence of MetS (Harmonized) (%)
Male Female *p-value
589 472 -
14 (50.0) 18 (60.0) >0.050
110 (84.0) 87 (97.8) <0.010
182 (97.8) 153 (98.7) >0.050
150 (83.3) 135 (100) <0.001
57 (98.3) 58 (98.3) >0.050
518 (87.9) 454 (96.2) <0.001
972 (91.6)
80.3
d to compare the prevalence of metabolic syndrome between male and
Table 5 Prevalence of metabolic syndrome in the type 2
diabetic patients according to their place of residence
Defining
bodies
Sex n Place of residence *p-value
Urban Village
Total 860 626 (83.5) 234 (75.2) <0.010
WHO Male 470 368 (85.8) 102 (63.8) <0.001
Female 390 258 (80.4) 132 (87.4) >0.050
p-value <0.050 <0.001
Total 884 633 (84.4) 251 (80.7) >0.050
NCEP ATP III Male 462 353 (82.3) 109 (68.1) <0.001
Female 422 280 (87.2) 142 (94.0) <0.050
p-value >0.050 <0.001
Total 854 589 (78.5) 265 (85.2) <0.050
IDF Male 410 295 (68.8) 115 (71.9) >0.050
Female 444 294 (91.6) 150 (99.3) <0.010
p-value <0.001 <0.001
Total 972 687 (91.6) 285 (91.6) >0.050
Harmonized Male 518 383 (89.3) 135 (84.4) >0.050
Female 454 304 (94.7) 150 (99.3) <0.050
p-value <0.010 <0.001
Values are presented as n (%). *p-values (2-tailed): Chi-square tests were
performed to compare the prevalence of MetS between male and female
patients residing in urban and village areas (rows) and within the individual
place of residence (column).
Table 6 Prevalence of metabolic syndrome in the type 2 diab
Ethnic groups
Defining bodies Sex n Brahman Chhet
WHO Total 860 181 (69.3) 187 (7
Male 470 124 (85.5) 109 (6
Female 390 57 (49.1) 78 (86
*p-value <0.001 <0.010
NCEP ATPIII Total 884 204 (78.2) 196 (7
Male 462 109 (75.2) 117 (7
Female 422 95 (81.9) 79 (87
p-value >0.050 <0.010
IDF Total 854 178 (68.2) 214 (8
Male 410 87 (60.0) 124 (7
Female 444 91 (78.4) 90 (10
p-value <0.010 <0.001
Harmonized Total 972 217 (83.1) 233 (9
Male 518 116 (80.0) 143 (8
Female 454 101 ((87.1) 90 (10
p-value >0.050 <0.010
Values are presented as n (%). *p-values (2-tailed): Chi-square tests were performed
different ethnic groups (rows) and within the individual ethnic groups (column). ǂNo s
definition is a constant.
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Dalit female patients had the highest (p <0.001) total
prevalence according to all four definitions. Prevalence
was also highest among Chhetri and Newar female
patients (p <0.001) according to IDF and Harmonized
definitions (Table 6). Depending on the definition used,
the prevalence of MetS was also found to have relation
with occupation of the study patients. Total prevalence
was significantly higher (p <0.05) in patients engaged in
agricultural activity according to all four definitions and
found to have relation with the gender. Male patients
engaged in agricultural activity had the highest preva-
lence according to WHO, NCEP ATPIII and Harmo-
nized definitions while it was highest among female
patients involved in business occupation according to
NCEP ATPIII and Harmonized definitions and office jobs
according to WHO and IDF definitions (Table 7). How-
ever, the difference in prevalence among females of differ-
ent occupations was not statistically significant (p >0.05)
except for the one defined by IDF criteria (p <0.001).
Prevalence of individual components of metabolic
syndrome
The frequencies of the number of MetS components
present in male and female patients are summarized in
Table 8. Majority of the Subjects had the cluster of four
metabolic abnormalities and the overall prevalence differed
significantly (p <0.05) between male and females. The
prevalence of individual MetS components included in theetic patients according to their ethnic background
ri Mongol Dalit Newar *p-value
3.9) 331 (95.1) 92 (90.2) 69 (71.1) <0.001
6.9) 159 (94.1) 47 (82.5) 31 (56.4) <0.001
.7) 172 (96.1) 45 (100.0) 38 (90.5) <0.001
>0.050 <0.010 <0.001
7.5) 309 (88.5) 98 (96.1) 77 (79.4) <0.010
1.8) 141 (83.4) 55 (96.5) 40 (72.7) <0.010
.8) 168 (93.9) 43 (95.6) 37 (88.1) <0.050
<0.010 >0.050 >0.050
4.6) 296 (85.1) 82 (80.4) 84 (86.6) <0.001
6.1) 120 (71.0) 37 (64.9) 42 (76.4) <0.050
0.0) 176 (98.3) 45 (100.0) 42 (100.0) <0.001
<0.001 <0.001 <0.010
2.1) 336 (96.6) 102 (100.0) 84 (86.6) <0.001
7.7) 160 (94.7) 57 (100.0) 42 (76.4) <0.001
0.0) 176 (98.3) 45 (100.0) 42 (100.0) <0.001
>0.050 ǂ <0.010
to compare the prevalence of MetS between the male and female patients of
tatistics were computed because metabolic syndrome defined by Harmonized
Table 7 Prevalence of metabolic syndrome in the type 2 diabetic patients according to their occupations
Defining bodies Sex n Agriculture Business Office job *p-value
WHO Total 860 422 (82.9) 260 (81.8) 178 (76.1) >0.050
Male 470 137 (83.5) 206 (82.1) 127 (73.0) <0.050
Female 390 285 (82.6) 54 (80.6) 51 (85.0) >0.050
p-value - >0.050 >0.050 >0.050 -
NCEP ATPIII Total 884 447 (87.8) 241 (75.8) 196 (83.8) <0.001
Male 462 141 (86.0) 177 (70.5) 144 (82.8) <0.001
Female 422 306 (88.7) 64(95.5) 52 (86.7) >0.050
p-value - >0.050 <0.001 >0.050 -
IDF Total 854 439(86.2) 236(74.2) 179 (76.5) <0.001
Male 410 109 (66.5) 180 (71.7) 121 (69.5) >0.050
Female 444 330 (95.7) 56 (83.6) 58 (96.7) <0.001
p-value - <0.001 <0.050 <0.001 -
Harmonized Total 972 479 (94.1) 286 (89.9) 207 (88.5) <0.050
Male 518 149 (90.9) 220 (87.6) 149 (85.6) >0.050
Female 454 330 (95.7) 66 (98.5) 58 (96.7) >0.050
p-value - <0.050 <0.010 <0.050 -
Values are presented as n (%). *p-values (2-tailed): Chi-square tests were performed to compare the prevalence of MetS between male and female patients of
different occupations (rows) and within the individual occupation (column).
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shown in Table 9. The most prevalent component was the
central obesity according to WHO (98.8%) and IDF (99.9%)
definitions. Decreased HDL-cholesterol was the second
most prevalent component according to NCEP ATPIII
(95.2%) and Harmonized (94.2%) definitions. Increased
BMI (≥30 kg/m2) was the least prevalent component (4.0%)
according to WHO definition while hypertension was the
least frequent component by the NCEP ATPIII (72.1%),
IDF (65.9%) and Harmonized criteria (67.0%).
Comparison between groups with and without metabolic
syndrome
The subjects with metabolic syndrome were compara-
tively older, more overweight or obese, hyperglycemic,
insulin resistant and suffering from diabetes for longerTable 8 Frequency of individual components of metabolic syn
MetS components WHO (1998) NCEP ATP (2001)
Male Female* Male Fe
n 589 472 589 47
1 6 (1.0) 1 (0.2) 25 (4.2) 4
2 102 (17.3) 82 (17.4) 102 (17.3) 46
3 230 (39.0) 149 (31.6) 179 (30.4) 65
4 251 (42.6) 240 (50.8) 222 (37.7) 15
5 - - 61 (10.4) 20
Values are presented as n (%). *p <0.050, **p <0.001 (two sided). Chi-square test wa
between male and female patients.duration. They had relatively poor glycemic control,
increased serum triglycerides, decreased serum HDL-
cholesterol and hypertension of at least four year duration.
BMI, waist circumference, HbA1C, serum triglycerides
and number of metabolic components were significantly
higher (p <0.05) in males with MetS whereas waist-hip
ratio and insulin resistance level were significantly
higher (p <0.05) in females with MetS diagnosed by
three or more definitions of metabolic syndrome. There
was no significant difference (p >0.05) in duration of
diabetes and hypertension, systolic and diastolic blood
pressure, fasting glucose, insulin and HDL-cholesterol
levels between male and female with MetS defined at
least by three definitions. Detailed comparison of clin-
ical and biochemical parameters between groups with
and without MetS is presented in Table 10.drome in the type 2 diabetic patients
IDF (2005) Harmonised (2009)
male** Male Female** Male Female**
2 589 472 589 472
(.8) 70 (11.9) 19 (4.0) 70 (11.9) 19 (4.0)
(9.7) 129 (21.9) 71 (15.0) 128 (21.7) 71 (15.0)
(13.8) 226 (38.4) 166 (35.2) 227 (38.5) 166 (35.2)
2 (32.2) 164 (27.8) 216 (45.8) 164 (27.8) 216 (45.8)
5 (43.4) - - - -
s performed to compare the number of components of metabolic syndrome
Table 9 Prevalence of individual metabolic abnormalities in the type 2 diabetic patients with metabolic syndrome
WHO NCEP ATP III
Prevalence (%) *p-value Prevalence (%) *p-value
Components of MetS Male Female Total Male Female Total
n 470 386 856 465 429 894
Increased FGǂ 470 (100) 386 (100) - 856 (100) 465 (100) 429 (100) - 894 (100)
BMI (≥30 kg/m2) 10 (2.1) 24 (6.2) <0.010 34 (4.0) - - -
Central obesity 460 (97.9) 386 (100) <0.010 846 (98.8) 132 (28.4) 368 (85.8) <0.001 500 (55.9)
Increased TG 368 (78.3) 303 (78.5) >0.050 671 (78.4) 363 (78.1) 324 (75.5) >0.050 687 (76.8)
Decreased HDL-C 373 (79.4) 344 (89.1) <0.001 717 (83.8) 425 (91.4) 426 (99.3) <0.001 851 (95.2)
Hypertension 300 (63.8) 267 (69.2) >0.050 567 (66.2) 350 (75.3) 295 (68.8) <0.050 645 (72.1)
IDF Harmonized
Prevalence (%) *p-value Prevalence (%) *p-value
Components of MetS Male Female Total Male Female Total
n 400 434 834 518 454 972
Increased FGǂ 400 (100) 434 (100) - 834 (100) 518 (100) 454 (100) - 972 (100)
Central obesity 400 (100) 433 (99.8) >0.050 833 (99.9) 399 (77.0) 433 (95.4) <0.001 832 (85.6)
Increased TG 268 (67.0) 304 (68.6) >0.050 572 (58.2) 367 (70.8) 324 (71.4) >0.050 691 (71.1)
Decreased HDL-C 349 (87.3) 431 (99.3) <0.001 780 (93.5) 468 (90.3) 451 (99.3) <0.001 819 (94.5)
Hypertension 256 (64.0) 286 (65.9) >0.050 542 (62.0) 355 (68.5) 296 (65.2) >0.050 651 (67.0)
Values are presented as n (%). ǂAll the study patients were considered to have increased fasting glucose as they were diagnosed type 2 diabetic patients and
taking medication for blood glucose control. *p-values (2-tailed): Chi-square test was performed to compare the mean proportions of metabolic components
between male and female patients.
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The agreement and disparity in the diagnosis of MetS
among WHO, NCEP ATP III, IDF and Harmonized
definitions is presented in the Table 11. The agreement
among these four definitions was substantial to slight.
The agreement was substantial between NCEP ATP III-
Harmonized (κ =0.62 (0.55-0.69), p <0.001), moderate be-
tween WHO-NCEP ATPIII (κ =0.51 (0.45-0.58), p <0.001)
and IDF-Harmonized (κ =0.51 (0.47-0.61), p <0.001),
fair between WHO-Harmonized (κ =0.37 (0.30-0.44),
p <0.001) and NCEP ATPII-IDF (κ =0.33 (0.26-0.40),
p <0.001) and slight between WHO-IDF definitions
(κ =0.27 (0.19-0.33), p <0.001). The Harmonized-NCEP
ATPIII and IDF definitions had the highest sensitivity
(99.9%) and negative predictive value (98.9%) whereas
NCEP ATPIII-Harmonized definitions had the highest
specificity (98.9%) and positive predictive value (99.9%).
Discussion
Irrespective of the defining criteria, our study revealed a
very high prevalence of MetS in Nepalese type 2 diabetic
patients, far higher than those reported in the general
population of Nepal and elsewhere [14,15,26-28]. Among
our diabetic patients, the highest prevalence rate was esti-
mated by Harmonized criteria (crude: 91.6%, age adjusted:
80.3%) followed by NCEP ATPIII (crude: 83.0%, age ad-
justed: 73.9%), WHO (crude: 81.1%, age adjusted: 69.9%)
and IDF criteria (crude: 80.5%, age adjusted: 66.8%),respectively. These seemingly different prevalence rates
arise due to the different cut-off points and sets of criteria
used by these four different definitions. The performance
of Harmonized criteria was the highest due to the removal
of central obesity as an obligatory component and inclu-
sion of any three of the five criteria present. This defin-
ition was introduced very recently in 2009 to bring the
harmony in the several existing definitions of the MetS
[8]. Studies that have used this definition also reported
very high prevalence of MetS confirming its improved
performance in other diabetic population too [29,30].
Because of the very high cut-off points for waist cir-
cumference, NCEP definition could identify relatively
low number of patients with central obesity. Similar
studies conducted in other subset of Nepalese diabetic
population have also reported relatively lower preva-
lence using this definition [17,18]. However, there was
little effect on the total prevalence rate due to freedom
of including any three components. The high preva-
lence of MetS among our patients was not surprising as
they were suffering from type 2 diabetes which itself
was an entity of the MetS. Several studies around the
globe have reported very high prevalence of MetS in
type 2 diabetic patients irrespective of the definitions
used, ethnicity and geographical area highlighting the
common etiology of MetS [17,29-31].
The gender distribution of the prevalence differed in
our subjects when based on NCEP ATP III, IDF and
Table 10 Comparison of anthropometric, biochemical and clinical parameters in the type 2 diabetic patients with and
without metabolic syndrome
WHO NCEP ATPIII
Variables With MetS Without MetS *p-value With MetS Without MetS *p-value
(n,%) 861 (81.5) 200 (18.5) <0.001 884 (83.2) 177 (16.8) <0.001
Age (year) 57.4 ±9.4 52.1 ±11.2 <0.001 56.9 ±9.5 53.5 ±11.7 <0.001
BMI (kg/m2) 23.8 ±2.9 23.0 ±2.1 <0.001 23.7 ±2.9 23.0 ±2.0 <0.001
WC (cm) 96.9 ±9.2 90.9 ±8.1 <0.001 96.8 ±9.3 90.4 ±6.9 <0.001
WHR 1.05 ±0.1 0.98 ±0.1 <0.001 1.04 ± .01 0.99 ±0.09 <0.001
FPG (mg/dl) 134.2 ±35.4 117.9 ±21.1 <0.001 132.9 ±34.9 122.0 ±25.8 <0.001
2 hr PMG (mg/dl) 226.5 ±63.8 182.1 ±39.4 <0.001 224.7 ±63.3 185.0 ±45.5 <0.001
EAG (mg/dl) 137.1 ±20.0 116.3 ±16.8 <0.001 136.5 ±20.1 116.6 ±17.3 <0.001
Hb1Ac% 6.4 ±0.7 5.7 ±0.6 <0.001 6.4 ±0.7 5.7 ±0.6 <0.001
Duration of DM (year) 6.5 ±4.7 4.0 ±3.6 <0.001 6.3 ±4.7 4.6 ±3.7 <0.001
TG (mg/dl) 223.0 ±195.8 136.3 ±61.3 <0.001 222.6 ±190.4 127.1 ±95.0 <0.001
TC (mg/dl) 239.9 ±67.1 183.1 ±37.4 <0.001 239.9 ±66.2 175.4 ±33.0 <0.001
VLDL (mg/dl) 44.5 ±29.2 27.5 ±12.3 <0.001 44.4 ±38.1 25.4 ±18.9 <0.001
HDL-C (mg/dl) 29.5 ±6.7 39.5 ±7.5 <0.001 29.5 ±6.8 40.7 ±6.3 <0.001
LDL-C (mg/dl) 165.9 ±61.0 116.2 ±35.3 <0.001 166.0 ±59.9 109.2 ±34.2 <0.001
SBP (mmHg) 135.2 ±15.0 120.8 ±11.6 <0.001 134.5 ±14.9 122.4 ±14.2 <0.001
DBP (mmHg) 84.1 ±8.8 76.9 ±5.5 <0.001 83.9 ±8.6 76.9 ±7.0 <0.001
Duration of HTN (year) 4.7 ±5.8 0.0 ±0.0 <0.001 4.5 ±5.8 0.6 ±1.9 <0.001
No. of MetS components 3.6 ±0.5 2.0 ±0.3 <0.001 4.0 ±0.8 1.8 ±0.4 <0.001
IDF Harmonized
Variables With MetS Without MetS *p-value With MetS Without MetS *p-value
n (%) 854 (80.5) 207 (19.5) <0.001 972 (91.6) 89 (8.4) <0.001
Age (year) 57.1 ±9.4 53.5 ±11.8 <0.001 56.9 ±9.5 50.5 ±12.7 <0.001
BMI (kg/m2) 24.1 ±2.6 21.6 ±2.2 <0.001 23.7 ±2.8 22.7 ±2.2 <0.001
WC (cm) 98.2 ±8.0 85.6 ±6.7 <0.001 96.4 ±9.2 88.8 ±7.5 <0.001
WHR 1.05 ±0.09 0.96 ±0.08 <0.001 1.0 ±0.1 0.95 ±0.1 <0.001
FPG (mg/dl) 131.2 ±30.8 130.9 ±43.9 >0.050 132.4 ±34.5 117.1 ±20.0 <0.001
2 hr PMG (mg/dl) 220.7 ±57.3 207.2 ±79.3 <0.050 222.6 ±62.6 167.9 ±30.5 <0.001
EAG (mg/dl) 135.9 ±20.6 122.0 ±19.0 <0.001 135.5 ±20.2 108.3 ±12.8 <0.001
Hb1Ac% 6.4 ±0.7 5.9 ±0.7 <0.001 6.3 ±0.7 5.4 ±0.5 <0.001
Duration of DM (year) 6.4 ±4.7 4.3 ±4.0 <0.001 6.2 ±4.7 3.7 ±3.6 <0.001
TG (mg/dl) 217.7 ±99.2 161.2 ±51.8 <0.001 214.3 ±187.7 123.2 ±25.7 <0.001
TC (mg/dl) 233.4 ±68.6 211.7 ±53.2 <0.001 234.3 ±66.4 173.2 ±32.6 <0.001
VLDL (mg/dl) 43.4 ±39.9 32.4 ±10.3 <0.001 42.8 ±37.6 25.1 ±5.5 <0.001
HDL-C (mg/dl) 30.7 ±7.4 34.2 ±9.2 <0.001 30.3 ±7.1 43.1 ±5.8 <0.001
LDL-C (mg/dl) 159.3 ±60.8 145.0 ±56.4 >0.010 161.2 ±60.0 105.0 ±33.7 <0.001
SBP (mmHg) 132.4 ±15.7 132.7 ±14.6 >0.050 132.9 ±15.3 128.3 ±16.9 <0.050
DBP (mmHg) 83.0 ±9.0 81.6 ±7.5 <0.050 83.1 ±8.9 78.7 ±6.7 <0.001
Duration of HTN (year) 4.3 ±5.8 2.0 ±3.5 <0.001 4.1 ±5.7 0.7 ±1.4 <0.001
No. of MetS components 4.2 ±0.7 3.0 ±0.9 <0.001 4.2 ±0.8 2.0 ±0.2 <0.001
Values are expressed as mean ± standard deviation.*p-values (2-tailed): Students t-test comparing the mean values of selected characteristics between patients
with and without MetS.
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Table 11 The concordance and diagnostic accuracy of WHO, NCEP ATPIII, IDF and Harmonized definitions in
identifying the cases of metabolic syndrome in the type 2 diabetic patients
Concordance Diagnostic Accuracy (%)
Definitions κ-value (95% CI) *p-value Agreement Sensitivity Specificity PPV NPV
WHO vs NCEP ATPIII 0.53 (0.45-0.58) <0.001 Moderate 90.0 71.4 92.8 63.5
NCEP ATPIII vs WHO 0.53 (0.45-0.58) <0.001 Moderate 92.8 57.5 90.4 65.0
WHO vs IDF 0.27 (0.19-0.33) <0.001 Slight 86.2 39.6 85.5 41.0
IDF vs WHO 0.27 (0.19-0.33) <0.001 Slight 85.5 41.0 86.2 39.6
WHO vs Harmonized 0.37 (0.30-0.44) <0.001 Fair 86.0 71.9 97.1 32.0
Harmonized vs WHO 0.37 (0.30-0.44) <0.001 Fair 97.1 32 86 71.9
NCEP ATPIII vs IDF 0.33 (0.26-0.40) <0.001 Fair 89.5 42.0 86.4 49.2
IDF vs NCEP ATPIII 0.33 (0.26-0.40) <0.001 Fair 86.4 49.2 89.5 42.0
NCEP ATPIII vs Harmonized 0.62 (0.55-0.69) <0.001 Substantial 90.8 98.9 99.9 49.7
Harmonized vs NCEP ATP III 0.62 (0.55-0.69) <0.001 Substantial 99.9 49.7 90.8 98.9
IDF vs Harmonized 0.54 (0.47-0.61) <0.001 Moderate 87.8 98.9 99.5 42.5
Harmonized vs. IDF 0.54 (0.47-0.61) <0.001 Moderate 99.9 42.5 87.8 98.9
Level of agreement and diagnostic accuracy are presented as κ-value (95% CI) and%, respectively. *p-values (approx. sig.). Chi-square test was used to compare
the level of agreement between two different definitions of MetS.
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females. However, no such difference was noted for the
prevalence estimated by WHO definition. Our female
patients were suffering from diabetes and hypertension
for longer duration, had relatively poor glycemic control
and were more obese and dyslipidemic than their male
counterpart which might explain why they have in-
creased prevalence of MetS. The less apparent gender
difference in prevalence by WHO definition might be
due to narrow differences in the sex–specific cut-off
values of waist-hip ratio and HDL-cholesterol as they
were the more prevalent components of MetS in our pa-
tients. It is possible that female patients of our study
sought medical treatment later in the disease than men
due to less access to finances and lack of awareness and
self-determination about their own health status. The
prevalence of MetS sharply increased with the age in
both men and women and remained highest in 50–69
years age range. This is expected because predisposition
of MetS in both men and women is strongly favored by
age related processes such as gradual decrease in the
basal metabolic rate, decreased growth hormone secre-
tion, hypogonadism, stress induced hypercortisolism, ab-
dominal fat deposition and concomitant insulin resistance
[1]. The sharp decline of the prevalence at very high age
group, on the other hand, might be due to increased fre-
quency of death of individuals who were most susceptible
to obesity related mortality such as coronary artery dis-
eases and cerebrovascular events [26,32].
Analysis of prevalence according to the place of resi-
dence revealed that male patients living in urban areas
had the much higher prevalence according to WHO and
NCEP ATPIII definitions while the opposite was trueaccording to NCEP ATPIII, IDF and Harmonized defini-
tions. The gender distribution of MetS within patients
residing in villages was also significant, with higher
prevalence in females by all four definitions. Similarly,
there was a significant difference in the prevalence
between females residing in urban and village areas.
Females residing in village area had higher prevalence
than the urban females by all four definitions, although
the difference was not significant for the WHO defined
prevalence. We also analyzed distribution of prevalence
according to ethnicity and occupational activity of the pa-
tients. Nepalese society is mainly agrarian in nature and a
mixture of two major ethnic groups: Indo-Aryans and
Mongoloids. Indo-Aryans are basically Hindus and are
further divided into several social caste systems such as
Brahmins, Chhetris, Vaishyas and Shudras or Dalits
(Kami, Damai, Sarki, Gandharva etc.), while Mongoloids,
although not divided into castes, have several tribes and
lineages [33]. Analysis based on ethnicity revealed that
total prevalence was the highest among Mongol, Dalit and
Newar patients. Dalit female patients had consistently
higher prevalence of MetS by all four definitions. In
addition, prevalence was also highest among Chhetri and
Newar female patients according to IDF and Harmonized
definitions. However, it was highest among Mongoloid
male patients by WHO, Dalit patients by NCEP ATPIII
and Harmonized and Newar patients by IDF definitions.
Likewise, prevalence was higher among patients who were
associated with agriculture and particularly among males.
In females, prevalence was higher among those who were
involved either in business or office job. It has been estab-
lished by several studies that low socioeconomic status,
urban habitat, illiteracy, blue collar occupation and certain
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of MetS [28,34-36]. Majority of our patients associated
with agriculture profession were residing in the village
area and were either illiterate or moderately educated and
belonged to the family of low socioeconomic status. The
reasons for increased prevalence of MetS in urban patients
were seemed to be sedentary life-style due to their in-
volvement in business and office jobs, increased intake of
calorie rich foods and android type central obesity.
We found substantial level of agreement between NCEP
ATPIII and Harmonized definitions. NCEP ATPIII defin-
ition missed out only one diabetic patient having MetS
according to Harmonized definition. This high level of
concordance is not surprising given their identical criteria
except the waist circumference. The second highest agree-
ment was observed between NCEP ATPIII and WHO
definitions and the lowest was observed between IDF and
WHO definitions. The agreement was only fair between
WHO and harmonized definitions. Almost similar pattern
of agreement has been found between these pairs of defi-
nitions when used for other diabetic population [30,37].
From these observations, we can conclude that WHO,
NCEP ATPIII and Harmonized definitions can identify
patients with higher degree of insulin resistance and in-
creased risk of cardiovascular diseases, but IDF definition
can identify additional patients, not identified by the earl-
ier definitions. These additional patients were those who
are at increased risk of future CVDs but have lesser degree
of insulin resistance. Among the four definitions used,
harmonized definition was found to be the most sensitive
while NCEP ATP III and IDF definitions were found to be
most specific in identifying the cases of MetS.
Majority of our patients had a cluster of four compo-
nents of MetS included by all four definitions: central
obesity, high serum TG, low serum HDL-C and hyper-
tension. This type of clustering is a commonly observed
phenomenon among type 2 diabetic patients which sig-
nificantly increases the risk of CVDs [13,38]. We found
central obesity as the most prevalent component accord-
ing to WHO and IDF criteria and decreased HDL-
cholesterol according to NCEP and Harmonized criteria.
The lower prevalence of central obesity according to
the NCEP ATP III criteria must be due to its relatively
higher cut-off values for waist circumference and that
makes it less applicable criterion to the Nepalese popula-
tion because of their smaller body sizes. Prevalence of
BMI, central obesity and low HDL-C was significantly
higher in females. South Asians, which also includes
Nepali population, are shown to have increased visceral
fat, central obesity, dyslipidemia and insulin resistance
even at younger age group compared to their Western
counterparts which predisposes them to very high risk
of MetS, type 2 DM and cardiovascular diseases than
any other population in the world [39]. In order toaddress these issues, WHO and IDF have set lower cut-
off points for the BMI, waist circumference and waist
hip ratio for South Asians [7,20]. It may thus be argued
that central obesity and decreased HDL level can be
used as the strong diagnostic markers of MetS also in
Nepalese population. Hypertension, on the other hand,
was found to be the least prevalent component in our
study patients according to all four criteria and no sig-
nificant relation was found with gender except for the
prevalence estimated by NCEP ATP III definition. These
findings are consistent with the reports of earlier studies
conducted in Nepal [15,17,18] but conflicting with many
other international studies [30,37,40]. In our study, pa-
tients with MetS were found to be older, more dyslipid-
emic, obese and hypertensive for longer duration than
those without MetS which was quite expected and sup-
ported by many other studie [29,40]. These patients, thus,
bore very high cardiometabolic risk even when compared
to their diabetic counterparts without MetS [41].
Our study was a cross-sectional study conducted
among uncomplicated type 2 diabetic patients attending
a tertiary care teaching hospital located in the Western
Development Region of Nepal. It enrolled mainly those
patients who hailed from the different districts of this re-
gion of Nepal and therefore, may not necessarily repre-
sent entire Nepalese diabetic population. This study also
did not cover the effect of treatment in the variation of
MetS prevalence among the study patients. Despite these
limitations, our study is the first of its kind in Nepal and
reports the age adjusted prevalence rates of MetS among
type 2 diabetics using four most used defining criteria. It
also analyzes the prevalence rates according to the age-
group, gender, place of residence, occupations, ethnicity
and smoking and dietary habits of the study patients and
describes the relative similarities and differences of the
definitions used in identifying the cases of MetS. More-
over, it contributes to the mapping of epidemiology of
MetS in Nepal and serves as comparable baseline data
for health policy makers and researchers.
Conclusion
Our study highlights the alarmingly high prevalence of
MetS and the increased risk of strokes and cardiovascu-
lar diseases among Nepalese type 2 diabetic patients. It
also suggests that Harmonized and NCEP ATP III defini-
tions are better than WHO and IDF definitions in identi-
fying the cases of MetS among Nepalese diabetic patients.
We expect that these finding will prompt the concerned
authorities of Nepal to formulate strategies to prevent and
delay the onset of future complications among the diabetic
patients. These strategies might include launching aggres-
sive health education programs to increase the public
awareness about the preventive measures and negative
consequences of MetS and type 2 DM, investing more
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cessible to the general public and minimizing the indi-
vidual risk factors by active therapeutic intervention in
already affected individuals.
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